Persistent chemotherapy-induced alopecia markedly impacts self-esteem, treatment adherence and overall quality of life in cancer survivors. This expert commentary by Professor Azael Freites-Martinez, lead author of a recent international Delphi consensus study, highlights its key insights and essential recommendations, offering actionable advice for the multidisciplinary team involved in clinical management.
Persistent chemotherapy-induced alopecia (pCIA) is a complex and distressing dermatological adverse event, and a consequence of systemic cytotoxic chemotherapy. Additional risk factors, such as genetic predisposition, age and concurrent medical conditions, may also play a role.
Despite its prevalence and psychological impact, pCIA has lacked standardised diagnostic and therapeutic protocols. Clinicians have relied on inconsistent criteria, often extrapolating from low-quality or retrospective data.
Our consensus, led by the European Academy of Dermatology and Venereology (EADV)’s Task Force on Dermatology for Cancer Patients, and published in the EADV’s official journal, aimed to address these gaps by providing evidence-informed, expert-derived guidance on terminology, diagnostic criteria, grading systems and treatment algorithms, while also promoting consistency across oncological and dermatological care teams.
It was developed using a structured two-round Delphi methodology to formalise expert agreement in an area with limited high-quality prospective data. A panel of 15 international dermatologists, with expertise in oncodermatology and hair disorders, drawn from academic and high-volume clinical settings across Europe and the Americas, participated.
A total of 62 statements covering the definition, pathophysiology, diagnosis, grading, prevention and management of pCIA were generated from a comprehensive literature review and distributed via an anonymous online survey. Experts rated each statement on a five-point Likert scale, with an agreement of 75% or higher constituting strong consensus.
Defining pCIA and its causes
pCIA is defined as non-scarring hair loss that continues for more than six months following the cessation of chemotherapy. The term ‘persistent’ is preferred over ‘permanent’ to reflect the potential for recovery with timely intervention.
Unlike endocrine therapy-induced alopecia (EIA), which arises after complete regrowth and is linked to hormone therapy, pCIA emerges directly from cytotoxic injury and often presents as more diffuse, severe hair thinning. Differentiating these entities is essential, as they have distinct pathophysiological bases and therapeutic implications.
Most experts agreed that the main mechanism of pCIA is the depletion or destruction of hair follicle cells by chemotherapy, which interferes with the normal anagen cycle and leads to prolonged hair loss. Severity varies with the dose and type of chemotherapy. Additional hypotheses include inflammatory cytokine activity, oxidative stress and possible epigenetic modifications that prevent follicular recovery.
pCIA is most commonly associated with specific classes of cytotoxic agents, including taxanes – particularly paclitaxel and docetaxel – and anthracyclines such as doxorubicin and epirubicin, which the consensus panel consistently identified as the principal contributors.
These agents are widely used in adjuvant and neoadjuvant regimens for breast, ovarian and lung cancers, where durable remissions are achieved at the cost of substantial cytotoxic exposure.
Cyclophosphamide – an alkylating agent frequently included in breast cancer protocols – is also strongly associated with pCIA. High-dose thiotepa and busulfan, commonly used in conditioning regimens before haematopoietic stem cell transplantation, were similarly implicated. In these cases, the degree of follicular injury is often more extensive due to myeloablative dosing, bringing about irreversible damage to the follicular stem cell niche.
The risk is particularly notable with combination regimens including:
- TAC (docetaxel, doxorubicin, and cyclophosphamide)
- AC-T (doxorubicin and cyclophosphamide followed by paclitaxel)
- CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) or ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) protocols used in haematologic malignancies.
These multi-agent treatments exert cumulative and synergistic cytotoxic effects, amplifying follicular injury and prolonging follicular quiescence.
Notably, the consensus remarked that in polychemotherapy protocols, it is often difficult to isolate the contribution of individual agents because of overlapping mechanisms of follicle damage.
Diagnosing and grading pCIA
The diagnosis of pCIA is fundamentally clinical, requiring a careful synthesis of patient history, oncologic treatment timelines and characteristic patterns of hair loss. According to the consensus, a detailed treatment chronology is essential, and clinicians must determine the exact onset of alopecia relative to chemotherapy initiation and cessation.
This timeline helps to distinguish pCIA from other alopecias, such as EIA or alopecia associated with targeted therapy, which may arise before, during or after chemotherapy but are driven by different mechanisms.
On physical examination, pCIA usually presents as diffuse, symmetrical hair thinning involving the vertex and frontal scalp, often accompanied by reduced hair shaft diameter. This differs from androgenetic alopecia, which exhibits a patterned distribution and miniaturisation, and EIA, which may resemble androgenetic alopecia but occurs after initial regrowth and coincides with the onset of hormone therapy.
While trichoscopy can aid in excluding alternative diagnoses such as alopecia areata or scarring alopecias, its role in confirming pCIA is limited due to non-specific findings.
Similarly, scalp biopsy is generally reserved for diagnostic uncertainty, particularly when scarring alopecia, telogen effluvium or underlying autoimmune conditions are in the differential.
The Common Terminology Criteria for Adverse Events grading system (Grade 1: <50% hair loss, Grade 2: ≥50% requiring a wig) is widely used in oncology to document adverse events. Although widely recognised and supported by the panel, it lacks the granularity needed for dermatological evaluation.
Dean’s scale, which segments hair loss into more detailed brackets (0–25%, 25–50%, etc.), was therefore recommended as a complementary tool for its precision in assessing diffuse alopecia.
Treatment and preventive strategies
First-line treatments for pCIA include 2–5% topical minoxidil and 0.5–5 mg/day low-dose oral minoxidil, which promote hair cycling and follicular recovery. Second-line therapy includes 100 mg/day oral spironolactone, alone or in combination with minoxidil. For eyelash alopecia, topical bimatoprost 0.03% was advised. These agents have shown efficacy in cancer survivors and are generally well tolerated.
In patients with hormone receptor-positive breast cancer, oral finasteride, dutasteride, bicalutamide and dutasteride mesotherapy were discouraged due to potential hormonal interactions. Spironolactone was considered safer based on available evidence and lack of association with increased cancer recurrence.
Scalp cooling was strongly endorsed as a preventive measure. This works by inducing vasoconstriction and reducing follicular metabolism, limiting chemotherapeutic exposure. Its usefulness is well-documented, especially with taxanes, and no increase in scalp metastases has been observed. Supportive measures such as gentle hair care and patient education were also advocated.
Consensus was weaker for platelet-rich plasma, photobiomodulation and topical finasteride due to limited data and conflicting results. Small pilot studies and split-scalp trials have not consistently demonstrated benefit, and robust, randomised trials are needed. Until then, these interventions remain experimental.
Looking to the future
Our pCIA consensus offers clear, practical recommendations for clinicians and healthcare providers to support cancer survivors facing persistent hair loss.
As next steps, the panel unanimously agreed that further research is needed to investigate emerging therapies and better characterise the long-term effects of chemotherapy on hair loss.
Early recognition and multidisciplinary intervention by dermatology, oncology and pharmacy teams to refine diagnostic criteria and optimise treatment are also essential.
Embedding psychological support and alopecia management into survivorship care plans will further improve long-term patient outcomes, but, above all, continued education and raising awareness of pCIA are key.
Author
Azael Freites-Martinez MD
Co-chair of the European Academy of Dermatology and Venereology task force on Dermatology for Cancer Patients, and associate professor and oncodermatologist, Ruber Juan Bravo Hospital and European University of Madrid, Spain
This article was originally published by our sister publication Hospital Healthcare Europe.
